The placebo effect in irritable bowel syndrome trials: A meta-analysis

Neurogastroenterology and Motility

Volumn 17, Issue 3, 2005, Pages 332-340

  Patel, S M ^a   Stason, W B ^b   Legedza, A ^a,c   Ock, S M ^c   Kaptchuk, T J ^c   Conboy, L ^c   Canenguez, K ^a   Park, J K ^c   Kelly, E ^a   Jacobson, E ^c   Kerr, C E ^c   Lembo, Anthony J ^a,d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Dana 501 ^*  (United States)

Author keywords

Irritable bowel syndrome; Meta analysis; Placebo

Indexed keywords

ACTIVATED CARBON; ALVERINE CITRATE; AMITRIPTYLINE; CHLORDIAZEPOXIDE; CISAPRIDE; CLONIDINE; DESIPRAMINE; DIAZEPAM; DICYCLOVERINE; DOMPERIDONE; ISPAGULA; LEUPRORELIN; LIDAMIDINE; LOPERAMIDE; LOXIGLUMIDE; NALOXONE; OCTATROPINE METHYLBROMIDE; OTILONIUM BROMIDE; PEPPERMINT OIL; PHENYTOIN; PIRENZEPINE; PLACEBO; ROCIVERINE; TEGASEROD; TIMOLOL; TRIMEBUTINE; TRIMIPRAMINE;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DOSE RESPONSE; DRUG EFFECT; HUMAN; IRRITABLE COLON; META ANALYSIS; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

CLINICAL TRIALS; HUMANS; IRRITABLE BOWEL SYNDROME; PLACEBO EFFECT; POPULATION; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 20044379425     PISSN: 13501925     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2005.00650.x     Document Type: Conference Paper

References (78)

1. MacDonald AJ, Peden NR, Hayton R, Mallinson CN, Roberts D, Wormsley KG. Symptom relief and the placebo effect in the trial of an anti-peptic drug. Gut 1980; 22: 323-6.
2. de Craen AJ, Moerman DE, Heisterkamp SH, Tytgat GN, Tijssen JG, Kleijnen J. Placebo effect in the treatment of duodenal ulcer. Br J Clin Pharmacol 1999; 48: 853-60.
3. Ilnyckyj A, Shanahan F, Anton PA, Cheang M, Bernstein CN. Quantification of the placebo response in ulcerative colitis. Gastroenterology 1997; 112: 1854-8.
4. Su C, Lichtenstein GR, Krok K, Brensinger CM, Lewis JD. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004; 126: 1257-69.
5. Spiller RC. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med 1999; 107: 91S-7S.
6. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000; 133: 136-47.
7. Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988; 95: 232-41.
8. Thompson WG. Placebos: a review of the placebo response. Am J Gastroenterol 2000; 95: 1637-43.
9. Dobrilla G, Scarpignato C. Placebo and placebo effect: their impact on the evaluation of drug response in patients. Dig Dis 1994; 12: 368-77.
10. Camilleri M, Talley NJ. Pathophysiology as a basis for understanding symptom complexes and therapeutic targets. Neurogastroenterol Motil 2004; 16: 135-42.
11. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
12. Mathias JR, Clench MH, Reeves-Darby VG et al. Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Double-blind, placebo-controlled study. Dig Dis Sci 1994; 39: 1155-62.
13. Agresta A. Categorical Data Analysis. New York: John Wiley & Sons, 1990.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
15. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999; 18: 2693-708.
16. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
18. Stata v. StataCorp. Copyright 1984-2003. College Station, Texas, USA: Stata v. StataCorp.
19. Rajagopalan M, Kurian G, John J. Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol 1998; 13: 738-41.
20. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002; 287: 1840-7.
21. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. JAMA 1994; 271: 1609-14.
22. McQuay H, Carroll D, Moore A. Variation in the placebo effect in randomised controlled trials of analgesics: all is as blind as it seems. Pain 1996; 64: 331-5.
23. Moyad MA. The placebo effect and randomized trials: analysis of conventional medicine. Urol Clin North Am 2002; 29: 125-33, ix-x.
24. Delaney BC, Moayyedi P, Forman D. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2003: CD001961.
25. Saito YA, Locke GR, Talley NJ, Zinsmeister AR, Fett SL, Melton LJ III. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 2816-24.
26. Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003; 72: 115-27.
27. Evans M. Justified deception? The single blind placebo in drug research. J Med Ethics 2000; 26: 188-93.
28. Landin R, DeBrota DJ, DeVries TA, Potter WZ, Demitrack MA. The impact of restrictive entry criterion during the placebo lead-in period. Biometrics 2000; 56: 271-8.
29. Leber PD, Davis CS. Threats to the validity of clinical trials employing enrichment strategies for sample selection. Control Clin Trials 1998; 19: 178-87.
30. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344(Suppl. 2): 1594-602.
31. Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45(Suppl. 2): 1169-77.
32. Naliboff BD. Choosing outcome variables: global assessment and diaries. Gastroenterology 2004; 126: S129-34.
33. Brandt LJ, Bjorkman D, Fennerty MB et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97: S7-26.
34. Drossman DA, Corazziari E, Talley NJ. Rome II. The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology, and Treatment: a Multinational Consensus, 2nd edn. McClean, VA, USA: Degnon Associates, 2000.
35. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-31.
36. Soltoft J, Krag B, Gudmand-Hoyer E, Kristensen E, Wulff HR. A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome. Lancet 1976; 7: 270-2.
37. Milo R. Use of the peripheral dopamine antagonist, domperidone, in the management of gastro-intestinal symptoms in patients with irritable bowel syndrome. Curr Med Res Opin 1980; 6: 577-84.
38. Fielding JF. Double blind trial of trimebutine in the irritable bowel syndrome. Ir Med J 1980; 73: 377-9.
39. Longstreth GF, Fox DD, Youkeles L, Forsythe AB, Wolochow DA. Psyllium therapy in the irritable bowel syndrome. A double-blind trial. Ann Intern Med 1981; 95: 53-6.
40. Fielding JF. Timolol treatment in the irritable bowel syndrome. Digestion 1981; 22: 155-8.
41. Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with bentyl (dicyclomine hydrochloride). J Clin Gastroenterol 1981; 3: 153-6.
42. Guslandi M, Evangelista A, Testoni PA, Tittobello A. Clinical evaluation of octatropine methyl-bromide plus diazepam (Valpinax) in the treatment of the irritable bowel syndrome. Clin Trials J 1981; 18: 138-44.
43. Fielding JF. Domperidone treatment in the irritable bowel syndrome. Digestion 1982; 23: 125-7.
44. Golechha AC, Chadda VS, Chadda S, Sharma SK, Mishra SN. Role of ispaghula husk in the management of irritable bowel syndrome (a randomized double-blind crossover study). J Assoc Physicians India 1982; 30: 353-5.
45. Myren J, Groth H, Larssen SE, Larsen S. The effect of trimipramine in patients with the irritable bowel syndrome. A double-blind study. Scand J Gastroenterol 1982; 17: 871-5.
46. Arthurs Y, Fielding JF. Double blind trial of ispaghula/poloxamer in the irritable bowel syndrome. Ir Med J 1983; 76: 253.
47. Tripathi BM, Misra NP, Gupta AK. Evaluation of tricyclic compound (Timipramine) vis-a-vis placebo in irritable bowel syndrome. Double blind randomized study. J Assoc Physicians India 1983; 31: 201-3.
48. Chadda VS, Joshi KG, Chadda S. A double blind crossover study of diphenylhydantoin in irritable bowel syndrome. J Assoc Physicians India 1983; 31: 425-7.
49. Dew MJ, Evans BK, Rhodes J. Peppermint oil for the irritable bowel syndrome: a multicentre trial. Br J Clin Pract 1984; 38: 398.
50. Nash P, Gould SR, Bernardo DE. Peppermint oil does not relieve the pain of irritable bowel syndrome. Br J Clin Pract 1986; 40: 292-3.
51. Ghidini O, Saponati G, Intrieri L. Single drug treatment for irritable colon: rociverine versus trimebutine maleate. Curr Ther Res Clin Exp 1986; 39: 541-8.
52. Prior A, Whorwell PJ. Double blind study of ispaghula in irritable bowel syndrome. Gut 1987; 28: 1510-3.
53. Lucey MR, Clark ML, Lowndes J, Dawson AM. Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study. Gut 1987; 28: 221-5.
54. Greenbaum DS, Mayle JE, Vanegeren LE et al. Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci 1987; 32: 257-66.
55. Prior A, Wilson KM, Whorwell PJ. Double-blind study of an alpha 2 agonist in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1988; 2: 535-9.
56. Centonze V, Imbimbo BP, Campanozzi F, Attolini E, Daniotti S, Albano O. Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome. Am J Gastroenterol 1988; 83: 1262-6.
57. Gilvarry J, Kenny A, Fielding JF. The non-effect of pirenzepine in dietary resistant irritable bowel syndrome. Ir J Med Sci 1989; 158: 262.
58. Yadav SK, Jain AK, Tripathi SN, Gupta JP. Irritable bowel syndrome: therapeutic evaluation of indigenous drugs. Indian J Med Res 1989; 90: 496-503.
59. Dobrilla G, Imbimbo BP, Piazzi L, Bensi G. Long-term treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. Gut 1990; 31: 355-8.
60. Van Outryve M, Milo R, Toussaint J, Van Eeghem P. 'Prokinetic' treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol 1991; 13: 49-57.
61. Fowlie S, Eastwood MA, Prescott R. Irritable bowel syndrome: assessment of psychological disturbance and its influence on the response to fibre supplementation. J Psychosom Res 1992; 36: 175-80.
62. Snook J, Shepherd HA. Bran supplementation in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 511-4.
63. Cann PA, Rovati LC, Smart HL, Spiller RC, Whorwell PJ. Loxiglumide, a CCK-A antagonist, in irritable bowel syndrome. A pilot multicenter clinical study. Ann N Y Acad Sci 1994; 713: 449-50.
64. Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996; 31: 463-8.
65. Schutze K, Brandstatter G, Dragosics B, Judmaier G, Hentschel E. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 387-94.
66. Battaglia G, Morselli-Labate AM, Camarri E et al. Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther 1998; 12: 1003-10.
67. Farup PG, Hovdenak N, Wetterhus S, Lange OJ, Hovde O, Trondstad R. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol 1998; 33: 128-31.
68. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 1035-40.
69. Muller-Lissner SA, Fumagalli I, Bardhan KD et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-66.
70. Lembo T, Wright RA, Bagby B et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 2662-70.
71. Camilleri M, Chey WY, Mayer EA et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001; 161: 1733-40.
72. Novick J, Miner P, Krause R et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-88.
73. Hubner WD, Moser EH. Charcoal tablets in the treatment of patients with irritable bowel syndrome. Adv Ther 2002; 19: 245-52.
74. Glende M, Morselli-Labate AM, Battaglia G, Evangelista S. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2002; 14: 1331-8.
75. Olden K, DeGarmo RG, Jhingran P et al. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2002; 97: 3139-46.
76. Mitchell SA, Mee AS, Smith GD, Palmer KR, Chapman RW. Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebo-controlled trial. Aliment Pharmacol Ther 2002; 16: 1187-95.
77. Hawkes ND, Rhodes J, Evans BK, Rhodes P, Hawthorne AB, Thomas GA. Naloxone treatment for irritable bowel syndrome-a randomized controlled trial with an oral formulation. Aliment Pharmacol Ther 2002; 16: 1649-54.
78. Camilleri M, Kim D, McKinzie S et al. A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2003; 1: 111-21.